Home > Animal Health and Nutrition > Veterinary Pharmaceuticals > pet cancer therapeutics market
Get a free sample of Pet Cancer Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Pet Cancer Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market is highly competitive, with the presence of key players. The companies are striving focus on expanding their product portfolios through innovations in chemotherapy, immunotherapy, and targeted treatments. In addition, strategic partnerships, acquisitions, and investments in research and development further strengthens the market positions. Furthermore, the growing demand for advanced pet cancer treatments has led to increased competition, driving innovation and the introduction of novel therapeutics to meet diverse consumer needs.
Few of the prominent players operating in the pet cancer therapeutics industry include:
The U.S. held a significant position in the North American pet cancer therapeutics market in 2024 and is projected to dominate with a 9.3% CAGR throughout the forecast period, supported by advanced veterinary healthcare infrastructure and high pet ownership rates.
Key players in the industry include AB Science, Boehringer Ingelheim International, CureLab Oncology, Dechra Pharmaceuticals, Elanco Animal Health, ELIAS Animal Health, NovaVive, Qbiotics, Pfizer, Torigen, and Vibrac.
The dog segment dominated the market with a valuation of USD 402 million in 2024 due to the higher incidence of cancer in dogs compared to other pets.
The pet cancer therapeutics industry was valued at USD 477.1 million in 2024 and is estimated to grow at a 9.7% CAGR from 2025 to 2034, driven by the increasing trend of pet humanization.